{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=13", "query": { "intervention": "ABI-007(Abraxane)", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 2447, "total_pages": 245, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T03:48:11.563Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02640053", "title": "Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Carcinoma" ], "interventions": [ { "name": "Cryotherapy", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2015-12-23", "completion_date": "2018-10-05", "has_results": true, "last_update_posted_date": "2019-09-30", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 8, "location_summary": "Urbana, Illinois • Grand Rapids, Michigan • Rochester, Minnesota + 5 more", "locations": [ { "city": "Urbana", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Anderson", "state": "South Carolina" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02640053" }, { "nct_id": "NCT03129139", "title": "A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Gastric Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer Metastatic", "Colo-rectal Cancer", "Solid Tumor", "Solid Carcinoma", "Solid Carcinoma of Stomach", "Cancer of Stomach" ], "interventions": [ { "name": "Minnelide™Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Minneamrita Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2017-10-10", "completion_date": "2024-12-01", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03129139" }, { "nct_id": "NCT01962103", "title": "Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Ewing's Sarcoma", "Ewing's Tumor", "Sarcoma, Ewing's", "Sarcomas, Epitheliod", "Sarcoma, Soft Tissue", "Sarcoma, Spindle Cell", "Melanoma", "Malignant Melanoma", "Clinical Oncology", "Oncology, Medical", "Pediatrics, Osteosarcoma", "Osteogenic Sarcoma", "Osteosarcoma Tumor", "Sarcoma, Osteogenic", "Tumors", "Cancer", "Neoplasia", "Neoplasm", "Histiocytoma", "Fibrosarcoma", "Dermatofibrosarcoma" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "24 Years", "sex": "ALL", "summary": "6 Months to 24 Years" }, "enrollment_count": 107, "start_date": "2013-12-04", "completion_date": "2018-11-06", "has_results": true, "last_update_posted_date": "2019-12-27", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 2, "location_summary": "Phoenix, Arizona • New York, New York", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962103" }, { "nct_id": "NCT05226598", "title": "Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 739, "start_date": "2022-03-24", "completion_date": "2026-01-09", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 12, "location_summary": "Colorado Springs, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 8 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05226598" }, { "nct_id": "NCT00003387", "title": "Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "chemotherapy", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "1998-07", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2016-07-20", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 47, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003387" }, { "nct_id": "NCT03435250", "title": "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "AG-270", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2018-03-04", "completion_date": "2023-04-20", "has_results": false, "last_update_posted_date": "2024-07-25", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435250" }, { "nct_id": "NCT00607048", "title": "Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Paclitaxel + Carboplatin + CP-870,893", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 34, "start_date": "2007-11", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2017-03-27", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 4, "location_summary": "Los Angeles, California • Santa Monica, California • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00607048" }, { "nct_id": "NCT00112489", "title": "Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 55, "start_date": "2005-05", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-09-25", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 99, "location_summary": "Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112489" }, { "nct_id": "NCT06952504", "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1123, "start_date": "2025-05-22", "completion_date": "2032-05-24", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 53, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Solvang", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952504" }, { "nct_id": "NCT01447706", "title": "A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 223, "start_date": "2011-10", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-05-12", "last_synced_at": "2026-10-15T03:48:11.563Z", "location_count": 10, "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Bakersfield, California + 7 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01447706" } ] }